摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-(3-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylic acid | 1123514-33-9

中文名称
——
中文别名
——
英文名称
1-(2-(3-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylic acid
英文别名
1-[2-[3-[[5-[4-(difluoromethoxy)phenyl]pyrimidin-2-yl]amino]phenoxy]ethyl]piperidine-4-carboxylic acid
1-(2-(3-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylic acid化学式
CAS
1123514-33-9
化学式
C25H26F2N4O4
mdl
——
分子量
484.503
InChiKey
NLMZTSSGZIBYBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    35
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    96.8
  • 氢给体数:
    2
  • 氢受体数:
    10

反应信息

  • 作为产物:
    描述:
    ethyl 1-(2-(3-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylate 在 lithium hydroxide 、 盐酸 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 6.0h, 生成 1-(2-(3-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)phenoxy)ethyl)piperidine-4-carboxylic acid
    参考文献:
    名称:
    [EN] 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    [FR] COMPOSÉS ET COMPOSITIONS DE 5- (4- (HALOALKOXY) PHÉNYL) PYRIMIDINE-2-AMINE UTILISÉS COMME INHIBITEURS DE KINASES
    摘要:
    该发明提供了式(1)的化合物及其制药组合物,可用作蛋白激酶抑制剂,以及使用这些化合物治疗、改善或预防与异常或调节的激酶活性相关的疾病的方法。在某些实施方式中,该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor、b-raf激酶的疾病或紊乱的方法。
    公开号:
    WO2009026276A1
点击查看最新优质反应信息

文献信息

  • PYRAZOLE COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2128138A1
    公开(公告)日:2009-12-02
    The present invention aims to provide an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates to an agent for the prophylaxis or treatment of diabetes comprising a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof.
    本发明旨在提供一种用于预防或治疗糖尿病的药物,具有优越的降血糖作用,并且与较少的副作用,如体重增加等相关。本发明涉及一种用于预防或治疗糖尿病的药物,包括由以下式表示的化合物:其中每个符号如描述中所定义,或其盐,或其前药。
  • 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    申请人:Molteni Valentina
    公开号:US20110301175A1
    公开(公告)日:2011-12-08
    The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
    本发明提供了式(1)的化合物和其制备的药物组合物,其作为蛋白激酶抑制剂具有用途,以及使用这种化合物的方法来治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状。在某些实施例中,本发明提供使用这种化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor b-raf激酶异常激活的疾病或疾病的方法。
  • 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
    申请人:IRM LLC
    公开号:US08293757B2
    公开(公告)日:2012-10-23
    The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
    本发明提供了公式(1)的化合物及其制药组合物,其可用作蛋白激酶抑制剂,以及使用这些化合物治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状的方法。在某些实施例中,本发明提供了使用这些化合物治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor b-raf 激酶异常活化的疾病或症状的方法。
  • US8293757B2
    申请人:——
    公开号:US8293757B2
    公开(公告)日:2012-10-23
  • [EN] 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE 5- (4- (HALOALKOXY) PHÉNYL) PYRIMIDINE-2-AMINE UTILISÉS COMME INHIBITEURS DE KINASES
    申请人:IRM LLC
    公开号:WO2009026276A1
    公开(公告)日:2009-02-26
    The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
    该发明提供了式(1)的化合物及其制药组合物,可用作蛋白激酶抑制剂,以及使用这些化合物治疗、改善或预防与异常或调节的激酶活性相关的疾病的方法。在某些实施方式中,该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor、b-raf激酶的疾病或紊乱的方法。
查看更多